Supriya Lifescience informs about updates
Supriya Lifescience has informed that the US Food and Drug Administration (US FDA) conducted an inspection at the Company’s manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, from 2 February 2026 to 6 February 2026. The inspection concluded with the issuance of a Form 483 containing one (1) minor observation. The Company has adequately addressed the observation and has received the Establishment Inspection Report (EIR) indicating ‘Voluntary Action Indicated (VAI)’, signifying a successful completion of the inspection. The Company remains committed to maintaining full compliance with current Good Manufacturing Practice (cGMP) requirements across all its manufacturing facilities.
The above information is a part of company’s filings submitted to BSE.
